Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 10 | 2023 | 2127 | 0.830 |
Why?
|
| Atherosclerosis | 5 | 2025 | 830 | 0.590 |
Why?
|
| Cardiovascular Diseases | 6 | 2024 | 1863 | 0.530 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 274 | 0.520 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2023 | 359 | 0.410 |
Why?
|
| Echocardiography | 4 | 2023 | 1049 | 0.330 |
Why?
|
| Cardiology | 2 | 2024 | 472 | 0.310 |
Why?
|
| Hypertension | 3 | 2024 | 1287 | 0.300 |
Why?
|
| Ventricular Remodeling | 1 | 2008 | 174 | 0.290 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 624 | 0.280 |
Why?
|
| Heart Diseases | 2 | 2024 | 482 | 0.280 |
Why?
|
| Age of Onset | 2 | 2025 | 581 | 0.260 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2005 | 6 | 0.250 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2005 | 52 | 0.240 |
Why?
|
| NF-kappa B | 3 | 2003 | 455 | 0.240 |
Why?
|
| Patient Readmission | 2 | 2018 | 366 | 0.240 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2005 | 239 | 0.230 |
Why?
|
| Cardiologists | 1 | 2023 | 19 | 0.220 |
Why?
|
| Income | 1 | 2024 | 133 | 0.210 |
Why?
|
| Carotid Artery Diseases | 2 | 2015 | 147 | 0.210 |
Why?
|
| Cardiovascular System | 1 | 2024 | 99 | 0.210 |
Why?
|
| Cause of Death | 1 | 2024 | 458 | 0.200 |
Why?
|
| United States | 11 | 2024 | 10631 | 0.200 |
Why?
|
| Vascular Stiffness | 2 | 2015 | 75 | 0.200 |
Why?
|
| Aortic Valve | 1 | 2005 | 432 | 0.200 |
Why?
|
| Hospitalization | 3 | 2024 | 1726 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 398 | 0.190 |
Why?
|
| Warfarin | 1 | 2022 | 118 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1088 | 0.180 |
Why?
|
| Humans | 34 | 2025 | 123169 | 0.180 |
Why?
|
| Adult | 15 | 2025 | 29062 | 0.170 |
Why?
|
| General Practitioners | 1 | 2019 | 17 | 0.160 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 616 | 0.160 |
Why?
|
| Trypanosoma cruzi | 1 | 2021 | 229 | 0.150 |
Why?
|
| Middle Aged | 12 | 2025 | 25994 | 0.150 |
Why?
|
| Thrombosis | 1 | 2022 | 520 | 0.140 |
Why?
|
| Chagas Disease | 1 | 2021 | 287 | 0.140 |
Why?
|
| Physicians | 1 | 2023 | 584 | 0.140 |
Why?
|
| Apoptosis | 1 | 2003 | 1781 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 417 | 0.140 |
Why?
|
| Cocaine | 1 | 2018 | 206 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 233 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 478 | 0.130 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1000 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 202 | 0.120 |
Why?
|
| Male | 17 | 2025 | 60082 | 0.120 |
Why?
|
| Pericardial Window Techniques | 1 | 2015 | 6 | 0.120 |
Why?
|
| Postprandial Period | 1 | 2015 | 77 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 24 | 0.120 |
Why?
|
| Cardiac Tamponade | 1 | 2015 | 37 | 0.120 |
Why?
|
| Female | 18 | 2025 | 65500 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 746 | 0.120 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 64 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 451 | 0.120 |
Why?
|
| Peptide Fragments | 1 | 2018 | 747 | 0.120 |
Why?
|
| Carotid Arteries | 1 | 2015 | 151 | 0.120 |
Why?
|
| Risk Factors | 6 | 2025 | 10010 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 715 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 173 | 0.110 |
Why?
|
| Dietary Fats | 1 | 2015 | 296 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2019 | 972 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 2477 | 0.100 |
Why?
|
| Prevalence | 3 | 2024 | 2406 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 124 | 0.090 |
Why?
|
| American Heart Association | 2 | 2024 | 295 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2011 | 73 | 0.090 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 494 | 0.090 |
Why?
|
| Aged | 6 | 2024 | 19080 | 0.090 |
Why?
|
| Stroke Volume | 2 | 2023 | 445 | 0.090 |
Why?
|
| Inpatients | 2 | 2024 | 464 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 468 | 0.080 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2022 | 257 | 0.080 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 413 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2021 | 332 | 0.080 |
Why?
|
| Prognosis | 3 | 2025 | 4507 | 0.080 |
Why?
|
| Vena Cava, Superior | 1 | 2009 | 55 | 0.080 |
Why?
|
| Texas | 3 | 2024 | 3555 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2024 | 16021 | 0.080 |
Why?
|
| Young Adult | 4 | 2024 | 8863 | 0.070 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 145 | 0.070 |
Why?
|
| Drosophila Proteins | 2 | 2002 | 707 | 0.070 |
Why?
|
| Chest Pain | 1 | 2005 | 124 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2024 | 67 | 0.060 |
Why?
|
| Dyspnea | 1 | 2005 | 147 | 0.060 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 95 | 0.060 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 34 | 0.060 |
Why?
|
| Cytoprotection | 1 | 2003 | 39 | 0.060 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 41 | 0.060 |
Why?
|
| Lipopolysaccharides | 2 | 2002 | 290 | 0.060 |
Why?
|
| Ligation | 1 | 2003 | 132 | 0.060 |
Why?
|
| Heart Ventricles | 3 | 2022 | 759 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2025 | 3316 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1226 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 849 | 0.050 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 51 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 228 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 35 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2022 | 52 | 0.050 |
Why?
|
| Disease Progression | 1 | 2008 | 2025 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2024 | 233 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 113 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 214 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2024 | 269 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 6371 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 233 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 1262 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2024 | 218 | 0.050 |
Why?
|
| Shock, Septic | 1 | 2002 | 146 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2002 | 171 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 281 | 0.040 |
Why?
|
| Insect Vectors | 1 | 2021 | 109 | 0.040 |
Why?
|
| Echocardiography, Stress | 1 | 2020 | 15 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 212 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 1996 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 2003 | 526 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1496 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 2008 | 1026 | 0.040 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 84 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 525 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2002 | 372 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2024 | 1325 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1168 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 196 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2024 | 1009 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2018 | 9 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1168 | 0.040 |
Why?
|
| Cerebellum | 1 | 2002 | 414 | 0.040 |
Why?
|
| Atenolol | 1 | 2018 | 43 | 0.040 |
Why?
|
| Propanolamines | 1 | 2018 | 31 | 0.040 |
Why?
|
| Metoprolol | 1 | 2018 | 22 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 2388 | 0.040 |
Why?
|
| Propranolol | 1 | 2018 | 128 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 1118 | 0.040 |
Why?
|
| Telephone | 1 | 2018 | 110 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 581 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2018 | 73 | 0.040 |
Why?
|
| Sex Factors | 1 | 2021 | 1259 | 0.040 |
Why?
|
| Incidence | 1 | 2025 | 3047 | 0.040 |
Why?
|
| Heart | 1 | 2002 | 723 | 0.040 |
Why?
|
| Animals | 6 | 2021 | 33749 | 0.040 |
Why?
|
| Ischemia | 1 | 2020 | 344 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2002 | 976 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 19103 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 607 | 0.030 |
Why?
|
| Time Factors | 2 | 2018 | 6217 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 2830 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2003 | 667 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2015 | 940 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2015 | 47 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2015 | 12129 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 131 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 714 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 514 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 72 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3378 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2002 | 94 | 0.030 |
Why?
|
| Cyclic GMP | 2 | 2002 | 92 | 0.020 |
Why?
|
| Mice | 3 | 2003 | 17494 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 2 | 2002 | 186 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 2002 | 143 | 0.020 |
Why?
|
| Toll-Like Receptors | 2 | 2002 | 84 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2011 | 105 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 1388 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1070 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2002 | 863 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3666 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2802 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 125 | 0.020 |
Why?
|
| Hemodynamics | 2 | 2002 | 845 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2025 | 0.020 |
Why?
|
| Myocardium | 2 | 2002 | 984 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 1592 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 63 | 0.010 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2002 | 13 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2002 | 118 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 106 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 53 | 0.010 |
Why?
|
| Dimerization | 1 | 2002 | 144 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2003 | 179 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 347 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2002 | 170 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2002 | 142 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2002 | 167 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2002 | 289 | 0.010 |
Why?
|
| Antirheumatic Agents | 1 | 2003 | 115 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2056 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2002 | 809 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 675 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 2002 | 631 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2002 | 847 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 2696 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 1285 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3868 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 1695 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 2813 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 1401 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2002 | 3718 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4346 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2002 | 4489 | 0.010 |
Why?
|